This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Nisoldipine, Sular CR, Sular Extended Release Tablets
Description: Nisoldipine, the active ingredient in Sular, is a calcium channel blocker that prevents calcium from entering certain types of muscle cells. Because muscle cells need calcium to contract, calcium channel blockers prevent the cells from contracting and cause them to relax. Nisoldipine selectively relaxes the muscles of small arteries causing them to dilate but has little or no effect on muscles or the veins of the heart.
In January 2008, the FDA approved a new controlled-release formulation of Sular. The new formulation utilizes SkyePharma's patented Geomatrix technology, which is designed to provide a lower dose of Sular for each of its current doses.
Deal Structure: In August 1995, Bayer AG granted to Zeneca Limited, a predecessor entity to AstraZeneca, the exclusive right to market, distribute and sell products containing nisoldipine in the U.S.
In February 2002, First Horizon Pharmaceutical Corporation entered into a definitive agreement to acquire certain U.S. rights relating to Sular from AstraZeneca. The Company has also entered into a long-term manufacturing, supply and distribution agreement with Sular's current manufacturer Bayer AG. The purchase price for the transaction is $185 million plus the assumption of certain liabilities. In addition, the Company may pay up to $30 million in additional purchase price after closing, based on the achievement of certain performance milestones. As part of this transaction, Bayer will grant to First Horizon an exclusive ten-year license to its patents and other intellectual property for the sale of Sular in the United States. Bayer has also agreed to supply First Horizon with Sular during the...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd. Bayer AG
Pink Sheet In Brief: Zeneca's Sular
Additional information available to subscribers only: